How effective are two anti-clotting agents (heparin and bivalirudin) in the management of heart attack patients receiving Primary angioplasty (urgent procedure to restore blood flow to the heart by opening the blocked artery using small balloons and stents) treatment
- Registry ID
- EUCTR2011-005273-23
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE4
- Sponsor
- Liverpool Heart and Chest Hospital
- Start date
- 2012-01-30
- Completion date
- 2018-12-17
- Last update
- 2026-08-16
Conditions
- ST elevation myocardial infarction
Summary
Bivalirudin and heparin are two drugs used in heart attack patients to prevent blood clotting during treatment with Primary angioplasty. Primary angioplasty is an urgent treatment in heart attack patients required to restore blood flow to the heart by opening the blocked artery using small balloons and stents. The principal research question of our study is: Is there any difference in the efficacy and safety of the two study agents in the treatment of heart attack patients undergoing primary angioplasty?
Locations
View on source registry